ClinicalTrials.gg
RecruitingNCT06343805Updated Nov 12, 2026

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

A Phase 1 interventional study of LY5830966 in Primary Myelofibrosis, sponsored by Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Recruiting at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 12, 2026Study contact changedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
256
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 453 studies in Primary Myelofibrosis with a site in United States — 69 open to participants now, 104 under way, 12 of them phase 3. Primary Myelofibrosis · United States.

Planned enrollment
29th of 387
256 · median 40
Started
2024
with 15 others
Phase 1
117 of 453
26 open now
Primary completion
2027-06
later than 55 of 103 live
Registered
416th of 453
by date

Among the 453 studies in Primary Myelofibrosis with a site in United States, this one is the 29th largest by planned enrollment of the 387 interventional ones that give a count, is one of 16 that started in 2024, is one of 117 in phase 1, reaches primary completion later than 55 of the 103 other live ones, and was the 416th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

69 of the 453 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:

64 more — sign in →

All 69 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 453 studies in Primary Myelofibrosis with a site in United States, or all of them as a file.
02

Study summary

J8G-MC-JDIA (AJX-101) is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II Janus Kinase 2 (JAK2) inhibitor, LY5830966, in participants with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.

Read the detailed description

This is a phase 1, non-randomized, open-label study utilizing a 3+3 sequential dose escalation design followed by an expansion phase. The primary objective will be to evaluate the safety and tolerability of LY5830966 and establish a Maximally Tolerated Dose (MTD) and/or inform the establishment of a candidate Recommended Phase 3 dose (RP3D). The RP3D may be the maximally tolerated dose (MTD) or may be a dose below the MTD. The candidate RP3D will be based on adverse event (AE) pattern, pharmacokinetics (PK) and biomarker information, in addition to all available safety and efficacy data. Expansion cohorts will be enrolled to gather additional safety and efficacy information and to further refine input for future RP3D discussions. Eligible participants will have PMF, PPV-MF or PET-MF and will have either have relapsed after a response, or be refractory to, at least one prior type I JAK2 inhibitor therapy, either administered as monotherapy or in combination with another drug.

03

Conditions studied

  • Primary Myelofibrosis

Browse trials for

Keywords

  • Post-Essential Thrombocythemia Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • PMF
  • PPV-MF
  • PET-MF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PMF, post-PV MF, or post-ET MF.
  • Dynamic International Prognostic Scoring System (DIPSS) Intermediate-1, Intermediate-2 or High-risk MF with less than or equal to (≤)10% blasts, regardless of JAK2 mutation status.
  • Estimated spleen volume greater than or equal to (≥)450 cubic centimeter (cm ³)
  • Myelofibrosis Symptom Assessment Form, version 4.0 (MFSAF v.4.0) TSS ≥10, or at least 2 of 7 MFSAF-assessed symptoms with scores ≥3.
  • performance score (ECOG PS) of 0, 1, 2, or 3.
  • Prior therapy with at least 1 type I JAK2 inhibitor, and either failed to achieve a response or after achieving a response.
  • greater than or equal to 1,000 per microliter of blood (ANC ≥1.0×10\^9/L).
  • count ≥75×10\^9/L.
  • Estimated greater than or equal to 45 milliliters per minute per 1.73 square meters (eGFR ≥45 mL/min/1.73m²).
  • Serum total ≤2.0 × (ULN).
  • (AST) and alanine aminotransferase (ALT) ≤3.0 × upper limit normal (ULN).
  • ≤470 msec.

Polycythemia vera (PV) Only

  • Confirmed diagnosis of PV
  • Participants must have high-risk disease as defined by 60 years of age or older and/or have prior history of thrombotic event
  • R/R or intolerant to at least one including but not limited to interferon-based therapies, ruxolitinib, or hydroxyurea (HU) as defined by European LeukemiaNet (ELN) criteria

Exclusion criteria

Exclusion Criteria:

  • Prior splenectomy or splenic irradiation within 3 months.
  • Ongoing use of systemic at dose equivalent to greater than (>) 20 milligrams per day (mg/day) of prednisone.
  • Active, uncontrolled systemic infection or active or C
  • Chemotherapy in the previous 4 weeks or prior JAK2 inhibitor not discontinued per required prior to first dose
  • Peripheral neuropathy ≥ Grade 2 ( v 5.0).
  • Pregnant or breastfeeding: males planning to father a child during treatment and for 3 months after last dose.
  • Requirement for therapy with a medication that is a strong Cytochrome P450 3A4 inhibitor as a concomitant medication.
  • Currently on an interventional therapeutic trial in the treatment phase.
  • Significant cardiovascular disease
  • Active second primary (or diagnosed within 2 years) at high risk of progression, with standard exceptions (treated skin cancer, in situ cervical cancer, curatively treated localized breast/prostate cancer)
  • Prolongation of the corrected ≥470 millisecond during screening
  • Individual with a history of (noninfectious) pneumonitis/interstitial lung disease.

(1L) MF only:

  • Prior treatment with JAK2 inhibitors

High-risk R/R PV only:

  • Prior PV-directed therapy without required washout
  • Active or chronic bleeding within 2 months prior to enrollment
  • thrombosis (e.g., pulmonary embolism, deep vein thrombosis, or splenic vein thrombosis) within 2 months prior to enrollment
  • Requires phlebotomy at hematocrit levels \<45%.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
256 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Dose A of LY5830966 taken orally by participants.

    Drug: LY5830966

  • Experimental
    Cohort 2

    Dose B of LY5830966 taken orally by participants.

    Drug: LY5830966

  • Experimental
    Cohort 3

    Dose C of LY5830966 taken orally by participants.

    Drug: LY5830966

  • Experimental
    Cohort 4

    Dose D of LY5830966 taken orally by participants.

    Drug: LY5830966

  • Experimental
    Cohort 5

    Dose E of LY5830966 taken orally by participants.

    Drug: LY5830966

  • Experimental
    Dose Expansion Cohort 1

    Candidate RP3D of LY5830966 taken orally by participants.

    Drug: LY5830966

  • Experimental
    Dose Expansion Cohort 2

    Alternative candidate RP3D of LY5830966 taken orally by participants.

    Drug: LY5830966

  • Experimental
    Dose Exploration Cohort 1

    Dose F of LY5830966 taken orally by participants

    Drug: LY5830966

  • Experimental
    Dose Exploration Cohort 2

    Dose G of LY5830966 taken orally by participants

    Drug: LY5830966

  • Experimental
    Dose Exploration Cohort 3

    Dose H of LY5830966 taken orally by participants\[

    Drug: LY5830966

Interventions

  • DrugLY5830966

    Type II JAK2 Inhibitor

    Also known as: AJ1-11095

06

What researchers measure

Primary outcomes

  1. Number of patients with treatment-emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).

    Treatment Emergent AEs will be assessed during routine study visits and compared to Baseline to continuously evaluate safety and tolerability of LY5830966.

    Time frame: Baseline through study completion, an average of 1 year

  2. Number of patients with Dose Limiting Toxicities (DLTs)

    Protocol-defined potential DLTs will be assessed by the Safety Review Committee at routine intervals.

    Time frame: Baseline through study completion, an average of 1 year

  3. To establish the maximum tolerated dose (MTD) and/or recommended phase 3 dose (RP3D) of LY5830966

    Safety evaluations will occur consistently for each patient and across patients to assess MTD or RP3D. See description of safety evaluations described in outcomes 1 and 2 mentioned above.

    Time frame: Baseline through study completion, an average of 1 year

Secondary outcomes

  1. To assess clinical response to LY5830966 evaluated by the Total Symptom Score (TSS).

    Number and proportion of patients with an improvement of ≥50% from Baseline in Total TSS as well as time to TSS response and duration of TSS response using the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0. The TSS is a 7 question assessment form with lower scores indicating better outcomes.

    Time frame: Baseline through Week 24

  2. To assess clinical response to LY5830966 evaluated by spleen volume assessments.

    Spleen volume reduction (SVR) of ≥35% from Baseline measured by magnetic resonance imaging (MRI) or computed tomography (CT).

    Time frame: Baseline through Week 24

  3. To assess clinical response to LY5830966 evaluated by spleen length assessments.

    Proportion of subjects with ≥50% reduction in length of spleen assessed by palpation.

    Time frame: Baseline through Week 24

  4. To assess clinical response to LY5830966 evaluated through spleen size improvement.

    Time to spleen size improvement response measured by patient and across all patients.

    Time frame: Baseline through Week 24

  5. To evaluate the Area Under the Curve (AUC) of LY5830966

    AUC time curve from 0 to 24 hrs post dose and percent difference between intervals will be evaluated.

    Time frame: Pre dose and post dose Cycle 1 (Day 1, and Day 2 (24hrs post), and Cycle 2 (Day 1 and 24 hrs post).

  6. To evaluate the Cmax of LY5830966

    The maximum observed plasma concentration will be evaluated.

    Time frame: Pre dose and post dose Cycle 1 (Day 1, and Day 2 (24hrs post), and Cycle 2 (Day 1 and 24 hrs post).

  7. To evaluate the Tmax of LY5830966

    The duration of time taken to reach Cmax will be evaluated.

    Time frame: Pre dose and post dose Cycle 1 (Day 1, and Day 2 (24hrs post), and Cycle 2 (Day 1 and 24 hrs post).

  8. To evaluate the half-life of LY5830966

    The depletion of AJ1-00195 in the body will be observed over time.

    Time frame: Pre dose and post dose Cycle 1 (Day 1, and Day 2 (24hrs post), and Cycle 2 (Day 1 and 24 hrs post).

07

Study locations

17 of 21 sites recruiting
  • Stanford Cancer Institute
    Palo Alto, California 94304, United States
    Recruiting
    • William Shomali, MD · Contact650-498-6000
  • Moffitt Cancer Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Andrew Kuykendall, MD · Contact813-745-4639
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • Abdulraheem Yacoub, MD · Contact
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Gabriela Hobbs, MD · Contact617-724-1124
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Recruiting
    • Jacqueline Garcia, MD · Contact617-632-1906
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Kristen Pettit, MD · Contact734-647-2829
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Stephen Oh, MD · Contact314-362-8814
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering
    New York, New York 10021, United States
    Recruiting
    • Raajit Rampal, MD · Contact
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • John Mascarenhas, MD · Contact212-241-8839
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
    Recruiting
    • Michael Grunwald, MD · Contact980-442-4363
  • University of Cincinnati
    Cincinnati, Ohio 45221, United States
    Recruiting
    • Eric Vick, MD · Contact513-213-3203
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Recruiting
    • Uma Borate, MD · Contact614-685-9828
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Prithviraj Bose, MD · Contact713-792-7747
  • AP-HP Hopital Saint-Louis
    Paris, France
    Recruiting
    • Jean-Jacques Kiladjian · Contact
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
    Bologna, Italy, Italy
    Not yet recruiting
    • Francesca Palandri, MD · Contact
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Italy, Italy
    Not yet recruiting
    • Francesco Passamonti, MD · Contact
  • Hospital General Universitario Gregorio Maranon
    Madrid, Spain, Spain
    Recruiting
    • Santiago Osorio-Prendes, MD · Contact0034915868443
  • Hospital Clinic Barcelona
    Barcelona, Spain
    Recruiting
    • Ana Moreno Triguero · Contact
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
    Recruiting
    • Valentin Garcia-Gutierrez · Contact
  • Guy's Hospital
    London, UK, United Kingdom
    Not yet recruiting
    • Claire Harrison, MD · Contact07939059512
  • Genesis Cancer Care UK Limited - Oxford
    Oxford, UK, United Kingdom
    Not yet recruiting
    • Adam Mead, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Apr 3, 2024
StartActual
Oct 3, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 6 sites removed
Show 6 added (4 Italy, 2 Spain)
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola · Bologna, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · Milan, Italy
  • Hospital General Universitario Gregorio Maranon · Madrid, Spain
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola · Bologna, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · Milan, Italy
  • Hospital General Universitario Gregorio Maranon · Madrid, Spain
Show 6 removed
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola · Bologna, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · Milan, Italy
  • Hospital General Universitario Gregorio Maranon · Madrid, Spain
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola · Bologna, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · Milan, Italy
  • Hospital General Universitario Gregorio Maranon · Madrid, Spain
across 2 updates, Oct 9, 2026 – Nov 12, 2026
Start date
Oct 23, 2024→Oct 3, 2024
Oct 9, 2026
Contact
Study contact changed: d•••@ajaxtherapeutics.com · •••7250→L•••@lilly.com · •••4559; added c•••@lilly.com. See the current contact
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    3 sites added, 3 sites removed
    Show 3 added (2 Italy, 1 Spain)
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola · Bologna, Italy
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · Milan, Italy
    • Hospital General Universitario Gregorio Maranon · Madrid, Spain
    Show 3 removed
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola · Bologna, Italy
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · Milan, Italy
    • Hospital General Universitario Gregorio Maranon · Madrid, Spain
    Contact Study contact changed: d•••@ajaxtherapeutics.com · •••7250→L•••@lilly.com · •••4559; added c•••@lilly.com. See the current contact
  2. Oct 9, 2026
    3 sites added, 3 sites removed
    Show 3 added (2 Italy, 1 Spain)
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola · Bologna, Italy
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · Milan, Italy
    • Hospital General Universitario Gregorio Maranon · Madrid, Spain
    Show 3 removed
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola · Bologna, Italy
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · Milan, Italy
    • Hospital General Universitario Gregorio Maranon · Madrid, Spain
    Start date Oct 23, 2024→Oct 3, 2024
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06343805
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Oct 3, 2024
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion